Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment o…
$115.02+4.70%
报价 2026-11-13
市值
$7.97B
EV
$7.69B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -2.2%
$75.82$117.62
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| RYTMRhythm Pharmaceuticals, Inc. | $7.97B | +4.7% | +75.7% | 88.2% | – | – | – | |
| PTGXProtagonist Therapeutics, Inc. | $8.55B | -2.6% | +1101.1% | 99.2% | – | – | 77.2x | |
| KNSAKiniksa Pharmaceuticals, Ltd. | $7.57B | +0.1% | – | 54.3% | 64.5x | 49.8x | 36.8x | |
| RLAYRelay Therapeutics, Inc. | $4B | +0.1% | -23.4% | 89.7% | – | – | – | |
| VRDNViridian Therapeutics, Inc. | $3.51B | +1.3% | -12.1% | 93% | – | – | – | |
| STOKStoke Therapeutics, Inc. | $1.75B | +1.8% | -81.2% | 98.9% | – | – | – | |
| QUREuniQure N.V. | $1.67B | -3.3% | – | 22.8% | – | – | – | |
| MGTXMeiraGTx Holdings plc | $881.7M | +4.4% | +1275.9% | 91.6% | – | – | – | |
| SNDXSyndax Pharmaceuticals, Inc. | $850.8M | -0.9% | +86.5% | 96% | – | – | – | |
| 同行中位数 | – | – | +37.2% | 92.3% | 64.5x | 49.8x | 57.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。